Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results

Globe Newswire - Wed Nov 3, 2021

- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 -

- Continued progress with SGT-003; Solid’s next-generation Duchenne gene therapy program demonstrates enhanced muscle tropism and microdystrophin expression -

Read more at globenewswire.com

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).